Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human PLAU Antikörper:
anti-Mouse (Murine) PLAU Antikörper:
anti-Rat (Rattus) PLAU Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal PLAU Primary Antibody für FACS, IHC (p) - ABIN1882148
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PLAU Primary Antibody für ELISA (Capture), ELISA (Detection) - ABIN491262
Botkjaer, Deryugina, Dupont, Gårdsvoll, Bekes, Thuesen, Chen, Chen, Ploug, Quigley, Andreasen: Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. in Molecular cancer research : MCR 2012
Show all 3 Pubmed References
Human Monoclonal PLAU Primary Antibody für ELISA (Capture), ELISA (Detection) - ABIN491259
Florova, Azghani, Karandashova, Schaefer, Koenig, Stewart-Evans, Declerck, Idell, Komissarov: Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. in American journal of respiratory cell and molecular biology 2015
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody für ELISA, WB - ABIN250818
Morgan, Hill: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. in Cancer cell international 2005
Human Polyclonal PLAU Primary Antibody für IHC (p), IHC - ABIN439170
Lee, Oh, Park, Na, Gil, Yang, Lee, Hong: Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis. in The Korean journal of internal medicine 2014
Mouse (Murine) Polyclonal PLAU Primary Antibody für ELISA (Detection), IHC (fro) - ABIN491326
Zhang, Kernan, Thomas, Collins, Song, Li, Zhu, Leboeuf, Eddy: A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. in The Journal of biological chemistry 2009
Human Polyclonal PLAU Primary Antibody für ELISA, WB - ABIN2477037
Woo, OBrien, Gillies, Etheridge: Mechanical and radiation isocenter coincidence: an experience in linear accelerator alignment. in Medical physics 1992
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody für EIA, IHC (fro) - ABIN191518
Coy, Jiménez-Movilla, García-Vázquez, Mondéjar, Grullón, Romar: Oocytes use the plasminogen-plasmin system to remove supernumerary spermatozoa. in Human reproduction (Oxford, England) 2012
The personalization of the patients' treatment using uPA (zeige PRAP1 Antikörper)/PAI-1 (zeige SERPINE1 Antikörper) tumor levels allows the reversion of the well-known poor prognostic impact of high uPA (zeige PRAP1 Antikörper)/PAI-1 (zeige SERPINE1 Antikörper) levels and strongly supports the use of this biomarker in clinical practice.
High Expressions of PLAU is associated with lung adenocarcinoma.
Adjuvant chemotherapy was 9% less likely to be recommended by a multidisciplinary board when using the current criteria compared with using a combination of the St. Gallen criteria and Ki67 (zeige MKI67 Antikörper) and uPA (zeige PRAP1 Antikörper)/PAI-1 (zeige SERPINE1 Antikörper) status (P = 0.03). Taken together, our data show discordance among markers in identifying the risk of recurrence, even though each marker may prove to be independently valid.
Increased expression of uPA (zeige PRAP1 Antikörper) in epidermal cells in psoriasis and in tumor cells in basal cell carcinomas suggests an important role of the uPA (zeige PRAP1 Antikörper) system for aggressively proliferating and invading cells of epidermal origin.
study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA (zeige PRAP1 Antikörper) and uPAR (zeige PLAUR Antikörper)
uPA (zeige PRAP1 Antikörper) protection is independent of its catalytic activity, as the amino terminal fragment of uPA (zeige PRAP1 Antikörper) showed similar protection. A key enzyme for repairing oxidative DNA damage is the p53 (zeige TP53 Antikörper) target hOGG1. We found a significant increase of hOGG1 after pretreatment of HACM with uPA (zeige PRAP1 Antikörper). Knockdown of hOGG1 completely abrogated the protective effect of uPA (zeige PRAP1 Antikörper)
We show that the tumor-suppressive actions of MEPs are mediated by PAI-1 (zeige SERPINE1 Antikörper), uPA (zeige PRAP1 Antikörper) and its receptor, uPAR (zeige PLAUR Antikörper), and are sustained even in the presence of the CAFs (zeige TBX1 Antikörper), which themselves enhance DCIS tumorigenesis via IL-6 (zeige IL6 Antikörper) signaling.
Gelsolin (zeige GSN Antikörper) enhances the invasive capacity of colon cancer cells via elevating intracellular superoxide (O2.-) levels by interacting with Cu/ZnSOD (zeige SOD1 Antikörper), and gelsolin (zeige GSN Antikörper) gene expression positively correlates with urokinase plasminogen (zeige PLG Antikörper) activator (uPA (zeige PRAP1 Antikörper)), an important matrix-degrading protease invovled in cancer invasion.
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (zeige IL6 Antikörper) (40.2pg/mL), VEGF-A (zeige VEGFA Antikörper) (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (zeige PRAP1 Antikörper) (248.1pg/mL), sHER-2/neu (zeige ERBB2 Antikörper) (5010pg/mL) and PLGF (zeige PGF Antikörper) (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
Study provides evidence that the stimulation of u-PA/u-PAR (zeige PLAUR Antikörper) system contributes to the activated phenotype and function of cancer-associated fibroblasts during multiple myeloma.
downregulation of uPA could decrease the fertility of male mice, which may be caused by a reduction in sperm motility.
data presented here reveal important information about dynamics in uPA by demonstrating how various ligands can modulate uPA activity by mediating long-range conformational changes
Lymphangioleiomyomatosis is fatal lung disease associated with germline/somatic inactivating mutations in TSC2 (zeige TSC2 Antikörper) genes. Data suggest lung lymphangioleiomyomatosis lesions and renal angiomyolipomas overexpress uPA; Tsc2 (zeige TSC2 Antikörper)-/- (or Tsc1 (zeige TSC1 Antikörper)-/-) embryonic fibroblasts from knockout mice express higher uPA levels than wild-type cells. (uPA = urokinase-type plasminogen activator; Tsc (zeige SLC12A3 Antikörper) = tuberous sclerosis complex protein)
The findings suggest that the absence of uPA correlates with increased levels of Runx transcriptional regulators in a way that promotes inflammation-associated carcinogenesis.
an intricate link between caveolin-1 (zeige CAV1 Antikörper) and Src kinase (zeige CSK Antikörper)-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C (zeige SFTPC Antikörper) expression through p53 (zeige TP53 Antikörper) and uPA system-mediated cross-talk, is reported.
These studies identify uPA-dependent de-repression of vegfr1 (zeige FLT1 Antikörper) and vegfr2 (zeige KDR Antikörper) gene transcription through binding to HHEX/PRH (zeige HHEX Antikörper) as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF (zeige VEGFA Antikörper) and identifies a potential new target for control of pathologic angiogenesis.
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
GM-CSF (zeige CSF2 Antikörper) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (zeige PLAUR Antikörper))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Data suggest endogenous uPA activity plays important role in oocyte maturation; these studies were conducted using in vitro oocyte maturation techniques.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (zeige PLAUR Antikörper)) and plasminogen activator inhibitor-1 (PAI-1 (zeige SERPINE1 Antikörper)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR (zeige PLAUR Antikörper) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS (zeige IRF6 Antikörper) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (zeige PLAUR Antikörper) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen (zeige PLG Antikörper) activator/plasmin (zeige PLG Antikörper) system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 (zeige SERPINE2 Antikörper) production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein